Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Journal of Clinical Oncology

• Publication date

  2011-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2010.33.9101PMID 22025143
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Optimising the dose of capecitabine in metastatic breast cancer: confused, clarified or confirmed?

  2010cited by this paper
• Deriving a patient-based utility index from a cancer-specific quality of life questionnaire.

  2009cited by this paper
• Preliminary validation of an optimally weighted patient-based utility index by application to randomized trials in breast cancer.

  2009cited by this paper
• Adjuvant chemotherapy in older women with early-stage breast cancer.

  2009cited by this paper
• Adjuvant Chemotherapy in Older Women with Early-Stage Breast Cancer

  2009cited by this paper
• Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer.

  2008cited by this paper
• Chemotherapy in metastatic breast cancer: A summary of all randomised trials reported 2000-2007.

  2008cited by this paper
• Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840.

  2008cited by this paper
• Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment.

  2008cited by this paper
• Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer.

  2006cited by this paper
• Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer.

  2005cited by this paper
• Randomised, phase II trial comparing oral capecitabine (Xeloda®) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines

  2002cited by this paper
• Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.

  2002cited by this paper
• Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer.

  2001cited by this paper
• Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23.

  2001cited by this paper
• [New guidelines to evaluate the response to treatment in solid tumors].

  2000cited by this paper
• Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over.

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer.

  1999cited by this paper
• Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer.

  1999cited by this paper
• Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.

  1999cited by this paper
• Patient preferences for oral versus intravenous palliative chemotherapy.

  1997cited by this paper
• Chemotherapy for metastatic breast cancer--when is enough enough?

  1997cited by this paper
• Dynamic balanced randomization for clinical trials

  1993cited by this paper
• Quality-adjusted survival analysis.

  1991cited by this paper
• Dynamic balanced randomization for clinical trials.

  1991cited by this paper
• "Classical" CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. An EORTC Breast Cancer Co-operative Group Phase III Trial (10808).

  1991cited by this paper
• Quality adjusted survival analysis.

  1990cited by this paper
• Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowe

  1990cited by this paper
• Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies.

  1987cited by this paper

• Metronomic (mCHT) vs standard (sCHT) chemotherapy as first-line treatment in HR+/HER2- Metastatic Breast Cancer (MBC) patients following failure of endocrine treatments. The matched control VICTOR-15 study

  2026cites this paper
• Metastatic Lobular Breast Cancer: Outcomes of Patients Treated at a Single Tertiary Institution

  2025cites this paper
• Convenient but concerning: patients' experiences of metronomic chemotherapy in metastatic breast cancer

  2025cites this paper
• Efficacy and Safety of Oral 5-FU Derivatives After Progression of HR+/HER2− Metastatic Breast Cancer on CDK4/6 Inhibitor

  2025cites this paper
• Trifluridine-tipiracil in previously treated patients with oestrogen receptor-positive, HER2-negative metastatic breast cancer (BOOG 2019-01 TIBET trial): a single-arm, multicentre, phase 2 trial

  2025cites this paper
• Optimizing endocrine adjuvant therapy in HR+/HER2− breast cancer: supplemental strategies and innovations

  2025cites this paper
• Resource allocation for hospitals (Reach): A time-driven activity-based costing study of chemotherapy regimens in a single institution

  2025cites this paper
• Metronomic chemotherapy: bridging theory to clinical application in canine and feline oncology

  2024cites this paper
• The Prevalence of 5-Fluorouracil and Capecitabine Cardiotoxicity: A Systematic Review and Meta-Analysis

  2024cites this paper
• Metronomic chemotherapy and drug repurposing: A paradigm shift in oncology

  2024cites this paper
• Metronomic Chemotherapy in Breast Cancer as a Strategy to Deliver More Sustainable and Less Toxic Treatments: Time to Debunk the Myth?

  2024cites this paper
• Metronomic chemotherapy using capecitabine and cyclophosphamide in metastatic breast cancer – efficacy, tolerability and quality of life results from the phase II METRO trial

  2024cites this paper
• Metronomic chemotherapy in cancer treatment: new wine in an old bottle

  2024cites this paper
• KDM5 family as therapeutic targets in breast cancer: Pathogenesis and therapeutic opportunities and challenges

  2024cites this paper
• Patient preferences do matter: a discrete choice experiment conducted with breast cancer patients in six European countries, with latent class analysis

  2023cites this paper
• The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2022 edition

  2023cites this paper
• Efficacy of Metronomic Oral Vinorelbine, Cyclophosphamide, and Capecitabine vs Weekly Intravenous Paclitaxel in Patients With Estrogen Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: Final Results From the Phase 2 METEORA-II Randomized Clinical Trial.

  2023cites this paper
• Influence of age on pharmacokinetics of capecitabine and its metabolites in older adults with cancer: a pilot study

  2023cites this paper
• Breast Cancer Treatment and Outcomes in Nigeria: A Systematic Review and Meta-analysis

  2023cites this paper
• Optimizing the future: how mathematical models inform treatment schedules for cancer.

  2022cites this paper
• Lanolin-based dexpanthenol cream, topical hydrocortisone or observation in the prevention of capecitabine-induced hand-foot syndrome: a phase III trial

  2022cites this paper
• Efficacy of taxanes rechallenge in first-line treatment of early metastatic relapse of patients with HER2-negative breast cancer previously treated with a (neo)adjuvant taxanes regimen: A multicentre retrospective observational study

  2022cites this paper
• Single arm, phase two study of low-dose metronomic eribulin in metastatic breast cancer

  2021cites this paper
• Metronomic Chemotherapy

  2021influential citation
• Patient Eligibility and Results for Brain Metastasis in Phase 3 Trials of Advanced Breast Cancer: A Scoping Review

  2021cites this paper
• The Place of Chemotherapy in The Evolving Treatment Landscape for Patients With HR-positive/HER2-negative MBC.

  2021cites this paper
• Efficacy, Safety and Cost Effectiveness of Metronomic Low Dose Versus Intermittent High Dose Capecitabine in Metastatic Breast Cancer

  2021cites this paper
• Anthracycline-containing regimens or taxane versus S-1 as first-line chemotherapy for metastatic breast cancer

  2021cites this paper
• The prolonged clinical benefit with metronomic chemotherapy (VEX regimen) in metastatic breast cancer patients

  2021cites this paper
• A narrative review of chemotherapy in advanced triple negative breast cancer

  2021cites this paper
• Tamoxifen resistance alters sensitivity to 5-fluorouracil in a subset of estrogen receptor-positive breast cancer

  2021cites this paper
• Capecitabine for hormone receptor-positive versus hormone receptor-negative breast cancer.

  2021cites this paper
• Effect of Adjuvant Metronomic Capecitabine on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer-Reply.

  2021cites this paper
• A novel, more reliable approach to use of progression-free survival as a predictor of gain in overall survival: The Ottawa PFS Predictive Model.

  2020cites this paper
• N2-3 Stage Nasopharyngeal Carcinoma Patients With Cervical Node Necrosis And Extracapsular Spread Benefit From Capecitabine Maintenance Chemotherapy

  2020cites this paper
• Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015

  2020cites this paper
• Suggestions Regarding the GEICAM/2003-11_CIBOMA/2004-01 Trial: Future Treatment Options for Early Triple-Negative Breast Cancer.

  2020cites this paper
• Estimating the Risks from COVID-19 Infection in Adult Chemotherapy Patients

  2020cites this paper
• Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.

  2020cites this paper
• International Consensus Conference for Advanced Breast Cancer, Lisbon 2019: ABC5 Consensus – Assessment by a German Group of Experts

  2020cites this paper
• Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2−negative endocrine-refractory metastatic breast cancer

  2020cites this paper
• Continuous Ordinal Regression for Analysis of Visual Analogue Scales: The R Package ordinalCont

  2020cites this paper
• Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment: The SYSUCC-001 Randomized Clinical Trial.

  2020cites this paper
• Efficacy and tolerability of metronomic chemotherapy in patients with metastatic breast cancer - an international experience in west sweden and in the south of ireland.

  2020cites this paper
• A review of current progress in triple-negative breast cancer therapy

  2020cites this paper
• Estimating the Risk of Death from COVID-19 in Adult Cancer Patients

  2020cites this paper
• De-escalating cancer treatments during COVID 19 pandemic: Is metronomic chemotherapy a reasonable option?

  2020cites this paper
• Efficacy of utidelone plus capecitabine versus capecitabine for heavily pretreated, anthracycline- and taxane-refractory metastatic breast cancer: final analysis of overall survival in a phase 3 randomised controlled trial.

  2020cites this paper
• ABC5 – Internationale Konsensuskonferenz zum fortgeschrittenen Mammakarzinom, Lissabon, 16.11.2019 – Deutsche Expertengruppe kommentiert ABC5-Abstimmungsergebnisse

  2020cites this paper
• Chinese expert consensus on the clinical diagnosis and treatment of advanced breast cancer (2018)

  2020cites this paper
• Study Designs in Multi-arm Trials for Breast Cancer: A Systematic Literature Review of Major Journals

  2020cites this paper
• The efficacy of first-line chemotherapy in endocrine-resistant hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer

  2020cites this paper
• ABC5 International Consensus Conference on Advanced Breast Cancer, Lisbon, 16 November 2019

  2020cites this paper
• MOMENTUM: A Phase I Trial Investigating 2 Schedules of Capecitabine With Aflibercept in Patients With Gastrointestinal and Breast Cancer.

  2020cites this paper
• The role of chemotherapy in treatment of advanced breast cancer: an overview for clinical practice.

  2020cites this paper
• Commentary by the German panel of experts on the ABC5 voting results

  2020cites this paper
• Prevalence of comorbidity in cancer patients scheduled for systemic anticancer treatment in Austria

  2019cites this paper
• NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY

  2019cites this paper
• IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer.

  2019cites this paper
• Assessing the tolerability and efficacy of first-line chemotherapy in elderly patients with metastatic HER2−ve breast cancer

  2019influential citation
• Cytotoxics and Anti-angiogenics: Metronomic Therapies

  2019cites this paper
• Treatment of advanced breast cancer with a metronomic schedule of oral vinorelbine: what is the opinion of Italian oncologists?

  2018cites this paper
• Randomised phase III trial of vinflunine plus capecitabine versus capecitabine alone in patients with advanced breast cancer previously treated with an anthracycline and resistant to taxane

  2018cites this paper
• Ongoing unmet needs in treating estrogen receptor-positive/HER2-negative metastatic breast cancer.

  2018cites this paper
• Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor–Positive, HER2-Negative Advanced Breast Cancer: The BOLERO-6 Randomized Clinical Trial

  2018influential citation
• Phase II trial of eribulin mesylate as a first- or second-line treatment for locally advanced or metastatic breast cancer: a multicenter, single-arm trial

  2018cites this paper
• A retrospective study of concurrent chemoradiotherapy plus S-1 adjuvant chemotherapy on curative effect for treatment of patients with N3 stage nasopharyngeal carcinoma

  2018cites this paper
• Investigation into Enhancing Capecitabine Efficacy in Colorectal Cancer by Inhibiting Focal Adhesion Kinase Signaling

  2018cites this paper
• Metronomic Chemotherapy for First-Line Treatment of Metastatic Triple-Negative Breast Cancer: A Phase II Trial

  2018cites this paper
• Progression-free survival as a surrogate endpoint for overall survival in modern ovarian cancer trials: a meta-analysis

  2018cites this paper
• Pan-European Expert Meeting on the Use of Metronomic Chemotherapy in Advanced Breast Cancer Patients: The PENELOPE Project

  2018cites this paper
• Change in Survival in Metastatic Breast Cancer with Treatment Advances: Meta-Analysis and Systematic Review

  2018cites this paper
• The efficacy and toxicity profile of metronomic chemotherapy for metastatic breast cancer: A meta-analysis

  2017cites this paper
• Efficacy and safety of low-dose capecitabine plus docetaxel versus single-agent docetaxel in patients with anthracycline-pretreated HER2-negative metastatic breast cancer: results from the randomized phase III JO21095 trial

  2017cites this paper
• Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer

  2017cites this paper
• Radiotherapy‐assisted tumor selective metronomic oral chemotherapy

  2017cites this paper
• Metronome Chemotherapiekonzepte

  2017influential citation
• Chemotherapy Regimens in the Adjuvant and Advanced Disease Settings

  2017cites this paper
• Current achievements and future perspectives of metronomic chemotherapy

  2017cites this paper
• Metronomic chemotherapy: A relook at its basis and rationale.

  2017cites this paper
• Dynamic strategy for personalized medicine: An application to metastatic breast cancer

  2017cites this paper
• Metronomic chemotherapy for advanced breast cancer patients.

  2017cites this paper
• Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial

  2017cites this paper
• Evaluation of the clinical benefits of adjuvant capecitabine monotherapy in elderly women with breast cancer: A retrospective study.

  2017cites this paper
• Chemotherapy for advanced HER2-negative breast cancer: Can one algorithm fit all?

  2017cites this paper
• Clinical Value of Capecitabine-Based Combination Adjuvant Chemotherapy in Early Breast Cancer: A Meta-Analysis of Randomized Controlled Trials.

  2017cites this paper
• A comparison of toxicity profiles between the lower and standard dose capecitabine in breast cancer: a systematic review and meta-analysis

  2016cites this paper
• Combining Fulvestrant with Low-Dose Capecitabine is Effective and Tolerable in Woman with Metastatic Breast Cancer.

  2016cites this paper
• Metronomic chemotherapy for metastatic breast cancer – a systematic review of the literature

  2016cites this paper
• A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study

  2016cites this paper
• A network meta-analysis for toxicity of eight chemotherapy regimens in the treatment of metastatic/advanced breast cancer

  2016cites this paper
• Hormonal therapy might be a better choice as maintenance treatment than capecitabine after response to first-line capecitabine-based combination chemotherapy for patients with hormone receptor-positive and HER2-negative, metastatic breast cancer

  2016cites this paper
• Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial.

  2016cites this paper
• More options, more considerations: how new treatment options influence clinical decision making.

  2016cites this paper
• Comparison of the effectiveness and toxicity of neoadjuvant chemotherapy regimens, capecitabine/epirubicin/cyclophosphamide vs 5-fluorouracil/epirubicin/cyclophosphamide, followed by adjuvant, capecitabine/docetaxel vs docetaxel, in patients with operable breast cancer

  2016cites this paper
• Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial.

  2016cites this paper
• Improving preclinical cancer models: lessons from human and canine clinical trials of metronomic chemotherapy

  2016cites this paper
• Safety and Efficacy of Low-Dose Metronomic Capecitabine in the Treatment of Elderly Patients with Breast Cancer: Report of Two Cases and Literature Review *

  2016cites this paper
• A Clinical Phase II Study of Oral Vinorelbine in HER-2 Negative MetastaticBreast Cancer

  2016cites this paper
• Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

  2015cites this paper